Adare acquires Orbis for drug discovery

By The Science Advisory Board staff writers

May 4, 2020 -- Adare Pharmaceuticals on April 30 acquired pharmaceutical technology firm Orbis Biosciences. Financial details were not disclosed. The acquisition will enhance Adare's ability to manufacture products for the global pharmaceutical, animal health, and over-the-counter markets.

The deal will boost Adare's contract development and manufacturing organization business, it said. Orbis uses a single-step manufacturing process called Precision Particle Fabrication to produce drug particles that can be dosed orally or otically or injected, Adare Pharmaceuticals said. The manufacturing process consists of three platforms: Optimµm for oral delivery, Unisun for otic delivery, and Stratµm for injectable delivery, according to Adare.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.